Clinical trials: Folate
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03106077
- Testing
- Mirvetuximab Soravtansine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center